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A b s t r a c t
Introduction: Eosinophils contribute to the pathogenesis of inflammatory bow-
el disease (IBD) in the intestine. Eosinophilic cationic protein (ECP) is one of the
most important eosinophilic specific mediators released during activation. The
aim of the study was to evaluate the clinical value of serum ECP determination
in children with active and inactive IBD and its correlation with disease activity.
Material and methods: There were 125 children with IBD (63 with Crohn’s dis-
ease – CD, 44 with ulcerative colitis – UC, 18 indeterminate colitis – IC) enrolled
in the study. Among them 83 children were in the active phase of the disease,
while the remaining 42 were in remission. The control group consisted of 
56 healthy children. The ECP was assessed three times in children with active IBD,
at baseline and after 2 and 6 weeks of treatment and once in children with inac-
tive IBD and controls using fluoroenzymeimmunoassays.
Results: We found elevated ECP at baseline in the total active IBD group when
compared to the inactive IBD and control groups, decreasing during treatment.
Serum ECP was also elevated in the active UC and CD groups when compared
to the inactive UC and CD groups, and correlated with clinical UC and CD activ-
ity (R = 0.57 and R = 0.52, p < 0.05, respectively) and duration of the clinical
manifestation in UC (R = 0.62, p < 0.05) but not with the disease location in the
gastrointestinal tract, or endoscopic and histopathological activity.
Conclusions: Evaluation of serum ECP in children with IBD may be useful in dis-
ease activity assessment at onset and during the treatment.
Key words: eosinophilic cationic protein, inflammatory bowel disease, children.
Introduction
Ulcerative colitis (UC), Crohn’s disease (CD) and indeterminate colitis
(IC) are chronic diseases of the gastrointestinal tract belonging to the
inflammatory bowel diseases (IBD). Inflammatory bowel diseases are char-
acterized by chronic course of the disorder and periodic relapses. Inflam-
matory lesions in UC and IC are located in the mucosa of the colon, but in
CD they may be located in any region of the digestive tract. Inflammation
of the intestinal tissue is characterized by the accumulation of inflamma-
tory cells in the affected tissue and release of multiple inflammatory medi-
ators into the extracellular space [1, 2].
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Introduction
Ulcerative colitis (UC), Crohn’s disease (CD) and indeterminate colitis
(IC) are chronic diseases of the gastrointestinal tract belonging to the
inflammatory bowel diseases (IBD). Inflammatory bowel diseases are char-
acterized by chronic course of the disorder and periodic relapses. Inflam-
matory lesions in UC and IC are located in the mucosa of the colon, but in
CD they may be located in any region of the digestive tract. Inflammation
of the intestinal tissue is characterized by the accumulation of inflamma-
tory cells in the affected tissue and release of multiple inflammatory medi-
ators into the extracellular space [1, 2].
Results of the latest research studies confirmed
the multifactorial etiology of IBD, including both
genetic and environmental factors, although the
direct cause of IBD is still unknown [3, 4].
The incidence of IBD considerably increased in
Western Europe and USA in children and adoles-
cents during the last three decades while the age
of manifestation of the disease symptoms de -
creased [5, 6]. The results of the epidemiological
studies carried out in the last years confirm similar
trends in Poland [7, 8].
During the course of IBD, inflammatory lesions
occur in the intestine, including oedema of the
mucosa and ulcerations with depletion of the gob-
let cells and disturbance of mucus production [9].
In histopathological assessment of biopsy speci-
mens of the inflamed mucosa, intensive inflam-
matory infiltrations composed of lymphocytes, neu-
trophils and eosinophils were described. Eosinophils
also have the ability to migrate through the cells of
the intestinal mucosa epithelium and form crypt
abscesses in IBD [10]. Increased infiltrations of the
eosinophils were reported in the mucosa of the
colon in active UC patients when compared to pa -
tients in remission [11, 12]. 
Increased eosinophil infiltrations were also
described in the lamina propria of mucosa and sub-
mucosa of the colon in CD patients [13]. The acti-
vation of eosinophils in the inflammatory reaction
is closely related to the release of various inflam-
matory mediators. Eosinophilic cationic protein
(ECP) is one of the most important eosinophilic-
specific mediators involved in the inflammatory
response in IBD [14]. During the progression of the
inflammatory process, ECP released locally in the
inflamed mucosa is permeated to the circulation
and has a systemic impact. 
The detailed role of eosinophilic granulocytes
and the mediators secreted by them in the course
of IBD is still not fully clarified.
Disease activity assessment is very important in
the long-term care and treatment of children with
IBD, because of the chronic nature of the disease
and occurring relapses.
For full assessment of the severity of the disease
in the lumen of the gastrointestinal tract, endo -
scopy should be performed. However, because of
its invasive nature and the high cost, there is a need
to seek laboratory markers of disease activity, which
could be reliable in assessment of the intensity of
inflammatory lesions in the intestine.
There are no studies estimating the changes of
serum concentrations of ECP in children with active
and inactive IBD up to now.
The aim of our study was to evaluate the clini-
cal value of determination of serum ECP concen-
trations in children with active and inactive form of
IBD and their correlation with disease activity. 
Material and methods
One hundred twenty-five children with IBD 
(59 girls, 66 boys, average age: 12.5 years, range:
2.8-18.0) were enrolled in the study, including 
63 children with CD, 44 with UC and 18 with IC.
There were 83 children with active IBD (42 with CD,
28 with UC and 13 with IC) and 42 with inactive
IBD (21 with CD, 16 with UC and 5 with IC). The
control group consisted of 56 healthy children (30
boys, 26 girls, average age: 11.3 years, range: 3.5–
18.0) with no complaints from the gastrointestinal
tract.
The study was carried out in accordance with
the guidelines of the Declaration of Helsinki. The
study protocol was approved by the Jagiellonian
University Bioethical Committee and informed con-
sent to participate in the study was obtained from
all patients’ legal guardians and patients more than
16 years of age enrolled in the study.
The concentration of ECP in serum was deter-
mined three times in the acute phase of IBD, at the
baseline and after 2 and 6 weeks of treatment, and
once in children with IBD in remission and the con-
trol group, using commercially available fluoroen-
zymeimmunoassays (Unicap ECP, Pharmacia, Swe-
den).
The diagnosis of IBD was based on the Porto cri-
teria [15]. The clinical activity of UC and IC was
measured according to the modified Truelove-Witts
severity index and the clinical activity of CD was
measured with the pediatric Crohn’s disease activ-
ity index (PCDAI) [16]. The endoscopic and histo -
pathological activity was evaluated with the Roth
endoscopic scale and the histopathological stan-
dard scale [17, 18]. Additionally, the serological
parameters perinuclear anti-neutrophil cytoplasmic
antibodies (pANCA) and anti-Saccharomyces cere-
visiae antibodies (ASCA) were assessed.
Statistical analysis
The statistical analysis was performed with Sta-
tistica 7.0 software (StatSoft, Tulsa, USA) using
ANOVA and Scheffe’s test. Correlation coefficients
between variables were assessed using Pearson’s
linear correlation test. Serum ECP concentrations
were expressed as mean values and standard devi-
ations. Value of p < 0.05 was considered statisti-
cally significant.
Results
Assessing the serum ECP concentrations in the
total active IBD group, we found them elevated at
baseline compared to the inactive IBD group and
controls, decreasing after 2 and 6 weeks of the
treatment (Figures 1, 2). 
Assessing serum ECP concentrations in sub-
groups of active IBD children, we found them sta-
Clinical value of serum eosinophilic cationic protein assessment in children with inflammatory bowel disease
1144 Arch Med Sci 6, December / 2014
tistically significantly elevated in the active UC and
CD groups as compared to controls and inactive UC
and CD groups, whereas serum ECP concentration
in the active IC group was comparable to the con-
trol group. Additionally, serum ECP concentrations
strongly decreased after 2 weeks and continuous-
ly slightly decreased after 6 weeks of the treatment
in both active UC and CD groups, but increased in
the active IC group (Table I).
The serum ECP concentrations in the active UC
and CD groups correlated with the clinical disease
activity (R = 0.57 and R = 0.52, p < 0.05, respective-
ly) (Figures 3 and 4). They also correlated with 
the values of erythrocyte sedimentation rate (ESR)
(R = 0.60 and R = 0.44, p < 0.05, respectively) but
did not correlate with C-reactive protein values and
serological parameters (pANCA and ASCA) (Table II). 
Moreover, serum ECP concentrations correlated
with the duration of clinical manifestation of dis-
ease (R = 0.61, p < 0.05) only in the UC group and
not in CD and IC groups (Figure 5). 
There were also no statistically significant cor-
relations between serum ECP concentrations and
disease location in the gastrointestinal tract or with
endoscopic and histological activity in UC, CD and
IC groups.
Discussion
Eosinophil accumulation in the mucosa of the
involved intestine is a frequent feature in different
allergic and inflammatory disorders of the gas-
trointestinal tract [19]. 
The specific granules of the eosinophils contain
a number of highly cationic proteins such as ECP,
which has potent cytotoxic action and is released
after activation and stimulation of the cells [20]. They
play an important role in the development of inflam-
mation in the gastrointestinal tract in the course of
IBD [21]. The activation of eosinophils with increased
release of ECP into the extracellular space and stool
in adult patients both with UC and CD and their cor-
relation with disease activity were reported [22, 23].
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Figure 1. Serum ECP concentrations in active (ac IBD)
and inactive IBD (rem IBD) and control (C) groups
Values are expressed as mean and standard deviations; 
*p < 0.05 for ac IBD vs. rem IBD and C.
ac IBD rem IBD C
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Figure 2. Serum ECP concentrations in total IBD
group at baseline (IBD 1), and after 2 (IBD 2) and 
6 (IBD 3) weeks of treatment
Values are expressed as mean and standard deviations; 
*p < 0.05 for active IBD 1 vs. IBD 2 and IBD 3.
IBD 1 IBD 2 IBD  3
Groups Baseline After 2 weeks After 6 weeks
UC: 
Active (n = 28) 25.31 ±15.42* 9.19 ±5.84* 6.80 ±4.86*
Inactive (n = 16) 15.82 ±11.36*
CD: 
Active (n = 42) 26.91 ±13.95* 16.31 ±8.38* 12.53 ±7.56*
Inactive (n = 21) 16.14 ±13.51*
IC:
Active (n = 13) 18.80 ±11.25 23.83 ±10.76 24.09 ±12.54
Inactive (n = 5) 16.28 ±7.76
C:
(n = 56) 15.05 ±9.72*
Data expressed as mean values and standard deviations; *p < 0.05 for baseline vs values after 2 and 6 weeks.
Table I. Serum ECP concentrations in ulcerative colitis (UC), Crohn’s disease (CD), indeterminate colitis (IC) and con-
trol (C) groups during the treatment (µg/l)
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Papers published in recent years confirmed acti-
vation of eosinophils in the pathogenesis of IBD
both in animal model and in humans. 
Shichijo et al. reported that using anti-ECP anti-
bodies in the treatment of dextran sulfate sodium-
induced colitis in rats promoted intestinal wound 
healing and downregulated the immune response.
More over, anti-ECP antibodies suppressed histo -
pathological activity of the disease and increased
the regenerative processes in the colonic epitheli-
um [24]. 
There were no available studies assessing serum
ECP in children with IBD. There are only a few clini-
cal studies assessing ECP and its clinical value using
different methodologies and different materials in
children with IBD. Luck et al. assessing in vitro
released ECP from peripheral blood eosinophils in
children with IBD found increased concentrations of
ECP in patients with active UC and CD when com-
pared to patients in remission, but there were no dif-
ferences between UC and CD with the same clinical
activity of the disease. Additionally, the authors
observed a significant correlation of ECP concentra-
tions with the clinical activity of both UC and CD [12]. 
This observation is in concordance with our
results. In our study we also found similar correla-
tion ratios between serum ECP concentrations and
the UC and CD clinical activities (0.57 vs. 0.52). 
Troncone et al. assessed ECP concentrations in
whole-gut lavage fluid from children with IBD. They
also found significantly elevated ECP concentrations
in UC when compared to CD and in both CD and UC
children when compared to controls [25]. The
method used by the authors required a whole-gut
lavage with a nonabsorbable polyethylene glycol-
based solution, which needed the patient’s cooper-
ation and was more invasive for pediatric patients. 
There have been published several papers eval-
uating ECP concentrations and their correlation with
disease activity in adult patients with IBD. Saitoh
et al. assessed ECP concentrations in stool samples
of CD and UC patients and controls. They observed
significantly increased ECP concentrations in active
CD and UC patients compared to inactive ones and
controls. The authors also observed significantly
increased concentrations of ECP within the inactive
UC and CD patients and also in UC and CD patients
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Figure 3. Correlation of serum ECP concentrations
with clinical activity in UC group
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Figure 4. Correlation of serum ECP concentrations
with clinical activity in CD group
Mild             Moderate            Severe
Clinical activity
Regression Regression
Correlation coefficient = 0.57 Correlation coefficient = 0.52
Parameter UC CD
ESR R = 0.60, p < 0.05 R = 0.44, p < 0.05
CRP R = 0.42, p = NS R = 0.38, p = NS
Hb R = 0.45, p = NS R = 0,31, p = NS
Albumin R = 0.28, p = NS R = 0.41, p = NS
pANCA R = 0.51, p = NS R = 0.43, p = NS
ASCA R = 0.39, p = NS R = 0.47, p = NS
Table II. Correlation of serum ECP concentrations with
laboratory parameters in ulcerative colitis (UC) and
Crohn’s disease (CD) groups
ESR – erythrocyte sedimentation rate, CRP – C reactive protein, 
Hb – haemoglobin, pANCA – perinuclear anti-neutrophil cytoplasmic
antibodies, ASCA – anti-Saccharomyces cerevisiae antibodies.
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Figure 5. Correlation of serum ECP concentrations
with duration of clinical manifestation in UC group
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relapsing during the following 3 months compared
to non-relapsing patients [23]. 
The results of the study of Raab et al. described
the mucosal release of ECP in UC adult patients
assessed by intraluminal segmental perfusion of
the sigmoid colon and rectum, showing a several-
fold increase of ECP when compared to controls.
Moreover, ECP was markedly increased in the per-
fusate and related to the intensity of the inflam-
matory infiltrations in the mucosa [26]. 
Pronk-Admiraal et al. described elevated serum
ECP concentrations in active UC adult patients com-
pared to inactive ones and controls. Additionally,
a decrease in serum ECP concentrations was ac -
companied by a decrease of blood eosinophil count
and C-reactive protein during pharmacological treat-
ment in active UC [27].
The results of our study in IBD children are in con-
cordance with earlier data in adults. They showed
that ECP may play a similar role in the pathogenesis
of UC and CD both in children and adults.
Our results showed increased serum ECP con-
cen trations in active UC and CD children and adoles -
cents as compared to inactive UC and CD pa tients
and controls, decreasing during the treatment.
Serum ECP concentrations correlated with the clin-
ical disease activity and with ESR in both UC and
CD groups and with the duration of the clinical
manifestation in the UC group.
In conclusion, serum ECP concentrations are dif-
ferent among active and inactive IBD patients and
healthy children. They correlated with clinical activ-
ity of UC and CD and may be a useful inflammato-
ry indicator of disease activity assessment in chil-
dren with UC and CD, helping to evaluate and
monitor the severity of the disease at onset and
during the treatment.
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